Transforming growth factor-beta1 gene expression and cyclosporine A-induced gingival overgrowth: a pilot study

J Clin Periodontol. 2008 May;35(5):371-8. doi: 10.1111/j.1600-051X.2008.01216.x. Epub 2008 Mar 17.

Abstract

Aims: The relationship between gingival overgrowth (GO) induced by cyclosporine A (CsA) and transforming growth factor-beta1 (TGF-beta1) remains unclear. The aims of the present study were to evaluate TGF-beta1 gene expression under different immunosuppressive treatments and its association with TGF-beta1 gene functional polymorphism and GO in renal transplant recipients.

Material and methods: The study included 98 CsA-treated renal transplant recipients (with and without GO) and 44 tacrolimus-treated transplant patients (without GO). TGF-beta1 mRNA expression was measured using a real-time quantitative polymerase chain reaction assay. The levels were correlated with TGF-beta1 gene polymorphisms at codons 10 and 25, with different immunosuppressive treatment and GO.

Results: The level of TGF-beta1 gene expression was insignificantly lower in the CsA-treated group compared with the tacrolimus group, and significantly lower in the group with GO compared with patients without GO. In tacrolimus- and CsA-treated patients, but not in patients with GO, the level of TGF-beta1 gene expression was associated with functional phenotypes of TGF-beta1. The incidence, degree and extent of GO were higher in recipients with lower TGF-beta1 gene expression.

Conclusions: Lower level TGF-beta1 gene expression, not functional polymorphism, in patients treated with CsA may be considered to be a risk factor for GO.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Cyclosporine / adverse effects*
  • Female
  • Gene Expression
  • Gingival Overgrowth / blood
  • Gingival Overgrowth / chemically induced*
  • Gingival Overgrowth / genetics
  • Humans
  • Immunosuppressive Agents / adverse effects*
  • Immunosuppressive Agents / therapeutic use
  • Kidney Transplantation*
  • Male
  • Middle Aged
  • Pilot Projects
  • Polymorphism, Single Nucleotide
  • Risk Factors
  • Tacrolimus / therapeutic use
  • Transforming Growth Factor beta1 / biosynthesis*
  • Transforming Growth Factor beta1 / blood
  • Transforming Growth Factor beta1 / genetics

Substances

  • Immunosuppressive Agents
  • Transforming Growth Factor beta1
  • Cyclosporine
  • Tacrolimus